Source: Recombinant genetic engineering production, expressed in Escherichia coli.

一、Product Introduction

Aspartate insulin is expressed in Escherichia coli through recombinant DNA technology, and its amino acid sequence is replaced by aspartic acid at position 28 of the B chain of human insulin. This change makes it difficult for aspartic insulin to form hexamers, but rather exists in the form of monomers. So that it can be quickly absorbed after entering the body, which is a type of quick acting insulin analogue.

二、Product features

1、Product source: E.coli

2、Product appearance: White or almost white powder

3、Related substances:

B28 aspartic insulin isomer ≤ 1.0%,

The total sum of A21 aspartic insulin, B3 aspartic insulin, and B3 aspartic insulin isomers is ≤ 2.0%,

The total amount of other impurities is ≤ 1.5%.

4、Quality standard: Enterprise standard (in compliance with domestic IND requirements)

5、Storage conditions: Storage and transportation at -15 ℃ and below

6、Validity period: tentatively 24 months

三、Product advantages

1、Compliant with regulatory requirements: This raw material can be used for scientific research or exported as a formulation raw material. For detailed information, please consult our company.

2、Complete quality documents: There is a sound quality assurance system and quality documents, which can be applied for DMF.

3、No animal origin: Recombinant production, no external virus contamination, and no use of animal origin raw materials in the production process.

4、Stable quality: mass production can ensure stable and continuous batch production; The difference between product batches is small, and the quality is stable.

四、Related products

Recombinant human insulin, Deutschland insulin, and Icodec insulin.